MedTrace Logo

Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome

NCT04522297 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2020-08-21

No results posted yet for this study

Summary

Hepatorenal syndrome is a functional renal impairment occurring in cirrhotic patients . It develops secondary to splanchnic arterial vasodilatation which decreases the effective blood volume, activate the renin-angiotensin-aldosterone system, and stimulate of sympathetic nervous system.This study aims to compare the efficacy of nor-epinephrine versus midodrine/ octreotide, together with intravenous albumin on renal functions of patients with hepatorenal acute kidney injury.

Conditions

  • Hepato-Renal Syndrome

Interventions

DRUG

Midodrine/Octreotide

oral midodrine plus octreotide as subcutaneous injection

DRUG

Nor-epinephrine

Intravenous infusion norepinephrine

Sponsors & Collaborators

  • National Hepatology & Tropical Medicine Research Institute

    lead OTHER_GOV

Principal Investigators

  • Doaa Abdelaziz yousef, Ph.D · Fellow at The National Hepatology and Tropical Research medicine institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-15
Primary Completion
2020-01-23
Completion
2020-01-23

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04522297 on ClinicalTrials.gov